These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27709352)

  • 41. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Kahlert S; Stieber P
    Clin Chim Acta; 2014 Mar; 430():86-91. PubMed ID: 24412321
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.
    Rocca A; Cancello G; Bagnardi V; Sandri MT; Torrisi R; Zorzino L; Viale G; Pietri E; Veronesi P; Dellapasqua S; Ferrucci F; Luini A; Johansson H; Ghisini R; Goldhirsch A; Colleoni M
    Anticancer Res; 2009 Dec; 29(12):5111-9. PubMed ID: 20044624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer.
    Ma L; Yang HY; Han XH; Li J; Wang F; Zhang CL; Yao JR; Shi YK
    Chin Med J (Engl); 2012 Nov; 125(22):4104-10. PubMed ID: 23158151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
    Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
    Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Utility of serum human epidermal growth factor receptor-2 extracellular domain(HER2 ECD)assessment in patients with advanced or recurrent breast cancer and those who received neoadjuvant therapy].
    Makino H; Iraha M; Manba N; Hashidate H; Shiotani M
    Gan To Kagaku Ryoho; 2012 Feb; 39(2):237-40. PubMed ID: 22333634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
    Sett A; Borthakur BB; Bora U
    Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
    Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
    Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression.
    Zheng H; Zhong A; Xie S; Wang Y; Sun J; Zhang J; Tong Y; Chen M; Zhang G; Ma Q; Kai J; Guo L; Lu R
    Cancer Med; 2019 Feb; 8(2):679-685. PubMed ID: 30661303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.
    Baselga J; Cortés J; Im SA; Clark E; Ross G; Kiermaier A; Swain SM
    J Clin Oncol; 2014 Nov; 32(33):3753-61. PubMed ID: 25332247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
    Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer.
    Sorensen BS; Mortensen LS; Andersen J; Nexo E
    Anticancer Res; 2010 Jun; 30(6):2463-8. PubMed ID: 20651409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients.
    Peng Z; Liu Y; Li Y; Zhang X; Zhou J; Lu M; Li Q; Shen L
    Biomark Med; 2014; 8(5):663-70. PubMed ID: 25123035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade.
    Ignatov T; Eggemann H; Burger E; Fettke F; Costa SD; Ignatov A
    Breast Cancer Res Treat; 2015 Jun; 151(2):357-64. PubMed ID: 25926338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer.
    Petersen ER; Sørensen PD; Jakobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1483-92. PubMed ID: 23420288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.